We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Judge Finds No Direct Infringement In Strattera Suit

Law360 (May 21, 2009, 12:00 AM EDT) -- A federal judge has ruled that several generic-drug makers do not directly infringe a patent related to Eli Lilly & Co.'s drug Strattera, which is used to treat attention deficit/ hyperactivity disorder, because the patent covers a method rather than a drug.

Judge Dennis M. Cavanaugh of the U.S. District Court for the District of New Jersey ruled Wednesday that the generic companies — Sun Pharmaceutical Industries Ltd., Actavis Elizabeth LLC, Sandoz Inc., Mylan Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd. and Teva Pharmaceuticals USA Inc....
To view the full article, register now.